Table 7:
Efficacy of produced antiparasitic drugs in combating equine anoplocephalidosis
| Experiment number / group of animals | Test product | Dose (mg of active substance /kg BW) | Number of horses in group | % infected | EPGa mean | EEb % | P value e |
|---|---|---|---|---|---|---|---|
| 2 / Control | Placebo | – | 20 | 15.0 |
6.15±3.8
f 1.35±0.16 |
– | – |
| 2 / Treatment | PPIANk | 0.2 IVM 10.0 ALB 10.0 NSl |
16 | 0.0 |
0 0 |
100 | NA |
| 3 / Control | Placebo | – | 12 | 66.7 |
49.4±14.7 1.79±0.1 |
– | – |
| 3 / Treatment | PPIA-2-1m | 0.2 IVM 10.0 ALB |
14 | 14.3 |
6.1±2.8 1.31±0.07 |
78.6 | < 0.05 |
| 3 / Treatment | PPIA-2-3n | 0.2 IVM 3.0 ALB |
13 | 0.0 |
0 0 |
100 | NA |
| 3 / Treatment | PPIA-2-5o | 0.2 IVM 5.0 ALB |
11 | 0.0 |
0 0 |
100 | NA |
| 3 / Treatment | PPI-initialp | 0.2 IVM | 12 | 58.3 |
43.8±13.2 1.82±0.09 |
12.6 | NA |
| 3 / Treatment | PPA-initialq | 10.0 ALB | 10 | 30.0 |
8.9±5.4 0.92±0.17 |
78.6 | < 0.05 |
a-q
For the abbreviations see footnotes of Table 5.